Nature Communications (Jul 2022)

Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

  • Moataz Reda,
  • Worapol Ngamcherdtrakul,
  • Molly A. Nelson,
  • Natnaree Siriwon,
  • Ruijie Wang,
  • Husam Y. Zaidan,
  • Daniel S. Bejan,
  • Sherif Reda,
  • Ngoc Ha Hoang,
  • Noah A. Crumrine,
  • Justin P. C. Rehwaldt,
  • Akash Bindal,
  • Gordon B. Mills,
  • Joe W. Gray,
  • Wassana Yantasee

DOI
https://doi.org/10.1038/s41467-022-31926-9
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 11

Abstract

Read online

Only a minority of patients with non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitors. Here the authors design a nanosystem for the co-delivery of a PLK1 inhibitor and PD-L1 antibody, showing anti-tumor immune responses in preclinical lung cancer models.